The spectrum of nonalcoholic fatty liver disease: From steatosis to nonalcoholic steatohepatitis

Nonalcoholic fatty liver disease (NAFL) has been recognized only in the pas t 20 years. Autopsy studies indicate it is remarkably common, especially am ong obese persons and patients with type 2 diabetes. Although fatty liver a lone is usually benign, an identifiable subset of patients may be at risk o f progression to cirrhosis and liver failure. The role of liver biopsy is c ontroversial. No specific, effective therapy as yet exists, although manage ment of weight, lipid levels, and glucose levels is recommended.